Generic and biosimilar medicines: quid?
Once intellectual property protection, data and marketing exclusivity of reference medicines have expired, generic medicines and biosimilar medicines can enter the off-patent market. This market entry is conditional on the approval of marketing authorization, pricing and reimbursement. Given that th...
Main Author: | Steven Simoens |
---|---|
Format: | Article |
Language: | English |
Published: |
SEEd Medical Publishers
2012-12-01
|
Series: | Farmeconomia: Health Economics and Therapeutic Pathways |
Subjects: | |
Online Access: | https://journals.seedmedicalpublishers.com/index.php/FE/article/view/448 |
Similar Items
-
From generic to biosimilar drugs: why take an innovative pace?
by: Fereshteh Barei, et al.
Published: (2012-12-01) -
Generics and biosimilars in oncology
by: I. A. Gopienko, et al.
Published: (2020-04-01) -
Biosimilars: presumption of guilt
by: Marina Vladimirovna Shestakova, et al.
Published: (2011-12-01) -
INTERNATIONAL APPROACHES TO THE GOVERNMENT PRICE CONTROL OVER GENERICS AND BIOSIMILARS: A REVIEW
by: D. G. Tolkacheva, et al.
Published: (2018-02-01) -
INTERNATIONAL APPROACHES TO THE GOVERNMENT PRICE CONTROL OVER GENERICS AND BIOSIMILARS: A REVIEW
by: D. G. Tolkacheva, et al.
Published: (2018-02-01)